X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (390) 390
Patent (31) 31
Book / eBook (16) 16
Conference Proceeding (13) 13
Newspaper Article (8) 8
Book Chapter (5) 5
Book Review (4) 4
Dissertation (4) 4
Publication (3) 3
Magazine Article (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (177) 177
humans (137) 137
female (99) 99
male (72) 72
middle aged (54) 54
oncology (48) 48
animals (47) 47
aged (44) 44
adult (39) 39
analysis (37) 37
abridged index medicus (30) 30
surgery (30) 30
cancer (28) 28
chemotherapy (25) 25
treatment outcome (24) 24
breast cancer (23) 23
breast neoplasms - drug therapy (23) 23
mice (22) 22
research (20) 20
risk factors (19) 19
studies (19) 19
cells (18) 18
health aspects (18) 18
mortality (18) 18
expression (16) 16
follow-up studies (16) 16
prospective studies (16) 16
survival (16) 16
biochemistry & molecular biology (15) 15
breast neoplasms - pathology (15) 15
immunology (15) 15
prognosis (15) 15
risk (15) 15
antineoplastic combined chemotherapy protocols - therapeutic use (14) 14
chemotherapy, adjuvant (14) 14
medicine (13) 13
mice, inbred c57bl (13) 13
multidisciplinary sciences (13) 13
neoadjuvant therapy (13) 13
therapy (13) 13
trastuzumab (13) 13
aged, 80 and over (12) 12
medicine, general & internal (12) 12
physics (12) 12
prevalence (12) 12
proteins (12) 12
research article (12) 12
tumors (12) 12
cell biology (11) 11
children (11) 11
disease models, animal (11) 11
gene expression (11) 11
genetic aspects (11) 11
management (11) 11
time factors (11) 11
young adult (11) 11
biology (10) 10
cancer therapies (10) 10
cyclophosphamide - administration & dosage (10) 10
disease-free survival (10) 10
infectious diseases (10) 10
inflammation (10) 10
medical research (10) 10
physiological aspects (10) 10
public, environmental & occupational health (10) 10
united states (10) 10
adolescent (9) 9
antineoplastic combined chemotherapy protocols - adverse effects (9) 9
chemistry (9) 9
clinical trials (9) 9
cohort studies (9) 9
drug therapy (9) 9
identification (9) 9
mutation (9) 9
patients (9) 9
signal transduction (9) 9
stroke (9) 9
surgical adjuvant breast (9) 9
survival rate (9) 9
activation (8) 8
antibodies, monoclonal, humanized - administration & dosage (8) 8
breast neoplasms - metabolism (8) 8
breast neoplasms - mortality (8) 8
care and treatment (8) 8
child (8) 8
cross-sectional studies (8) 8
deoxyribonucleic acid--dna (8) 8
doxorubicin - administration & dosage (8) 8
flow cytometry (8) 8
genetics (8) 8
genetics & heredity (8) 8
guidelines (8) 8
hematology, oncology and palliative medicine (8) 8
incidence (8) 8
medical and health sciences (8) 8
medical colleges (8) 8
medicin och hälsovetenskap (8) 8
medicine & public health (8) 8
medicine, experimental (8) 8
mice, knockout (8) 8
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9938, pp. 164 - 172
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 12, pp. 1183 - 1192
Summary Background We studied the effect on tumour response to neoadjuvant therapy of the substitution of lapatinib for trastuzumab in combination with weekly... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | WOMEN | CELLS | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | ONCOLOGY | GW572016 | CHEMOTHERAPY PLUS TRASTUZUMAB | PERTUZUMAB | INHIBITOR | DOCETAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Puerto Rico | United States | Humans | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Protein Kinase Inhibitors - adverse effects | Molecular Targeted Therapy | Breast Neoplasms - enzymology | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Biomarkers, Tumor - metabolism | Mastectomy | Female | Neoadjuvant Therapy | Quinazolines - administration & dosage | Receptor, ErbB-2 - antagonists & inhibitors | Chemotherapy, Adjuvant | Biomarkers, Tumor - antagonists & inhibitors | Odds Ratio | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Drug Administration Schedule | Logistic Models | Treatment Outcome | Chi-Square Distribution | Breast Neoplasms - drug therapy | Canada | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Quinazolines - adverse effects | Trastuzumab | Health maintenance organizations | Neoadjuvant therapy | Medical colleges | Care and treatment | Cyclophosphamide | Anthracyclines | Adjuvant treatment | Breast cancer | Product development | Public health | Cancer | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 9, pp. 1037 - 1048
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2014, Volume 15, Issue 2, pp. 156 - 163
Journal Article
Pharmacognosy Magazine, ISSN 0973-1296, 7/2016, Volume 12, Issue 47, pp. 475 - 481
Background: α-glucosidase inhibitors controls postprandial hyperglycemia (PPHG) by lowering sharp rise in blood glucose levels after ingestion of carbohydrate... 
postprandial hyperglycemia | antioxidant | Albino-Wistar rats | Acalypha indica | a-glucosidase inhibitor | CHEMISTRY, MEDICINAL | ASSAY | PLANTS | Oxidative stress | Enzymes | Carbohydrates | Sucrose | Glucose | Insulin | Developing countries--LDCs | Antioxidants | Herbal medicine | Hyperglycemia | Rodents | Conflicts of interest | Diabetes | Original | Albino–Wistar rats
Journal Article
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2012, Volume 366, Issue 4, pp. 310 - 320
The addition of bevacizumab to neoadjuvant combination chemotherapy significantly increased the percentage of patients with a pathological complete response.... 
PROJECT PROTOCOL B-27 | TRIAL | MEDICINE, GENERAL & INTERNAL | SURGICAL ADJUVANT BREAST | PREOPERATIVE CHEMOTHERAPY | THERAPY | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | PHASE-III | DISEASE | DOCETAXEL | PACLITAXEL | Breast Neoplasms - surgery | Cyclophosphamide - administration & dosage | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bevacizumab | Angiogenesis Inhibitors - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Fluorouracil - administration & dosage | Mastectomy, Segmental | Adult | Female | Neoadjuvant Therapy | Angiogenesis Inhibitors - adverse effects | Doxorubicin - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Logistic Models | Treatment Outcome | Breast Neoplasms - drug therapy | Disease Progression | Taxoids - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Aged | Receptor, ErbB-2 | Deoxycytidine - analogs & derivatives | Drugs | Chemotherapy | Usage | Patient outcomes | Breast cancer | Product/Service Evaluations | Drug therapy | Cancer | Heart | Mucositis | Gemcitabine | Review boards | Body weight | Cancer therapies | Antimetabolites | Doxorubicin | ErbB-2 protein | Patients | Feet | Metastases | Cyclophosphamide | Epidermal growth factor | Ventricle | Taxanes | Neutropenia | Index Medicus | Abridged Index Medicus
Journal Article